Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência.
Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
I-Mab Biopharma has dosed the first patient in mainland China in its ongoing, pivotal Phase 2 trial assessing MorphoSys‘s investigational antibody therapy MOR202 (TJ202) as treatment for people with ... Read more
Treatment with Regeneron Pharmaceuticals‘ investigational therapy REGN5458 was well tolerated and significantly lowered the tumor burden in more than half of heavily treated multiple myeloma patients in a Phase ... Read more
Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare is setting up to develop a new treatment formulation delivered through a skin patch, maintaining an optimal blood level of the medicine ... Read more
An under-the-skin injection of daratumumab is as effective as its intravenous formulation, Darzalex (daratumumab), at reducing tumor burden in multiple myeloma patients, a Phase 3 clinical trial shows. The new ... Read more
Multiple myeloma patients who receive Ninlaro (ixazomib) maintenance after responding to their initial treatment live longer without their disease worsening or returning than patients given a placebo, a Phase 3 ... Read more
The U.S. Food and Drug Administration has approved a new dosing regimen for the multiple myeloma treatment Darzalex (daratumumab), allowing doctors to split the first infusion over two consecutive days. The ... Read more
Janssen Biotech has asked that the U.S. Food and Drug Administration to expand the label for Darzalex (daratumumab) to include its use, in combination with standard Revlimid (lenalidomide) and dexamethasone, as a first-line ... Read more
Long-term maintenance treatment with Revlimid (lenalidomide) significantly improves the length of time multiple myeloma patients live without disease worsening after their first-line therapy and, in some patients, also extends ... Read more
Pin It on Pinterest